ARIAD Pharmaceuticals (ARIA) : Traders are bullish on ARIAD Pharmaceuticals (ARIA) as it has outperformed the S&P 500 by a wide margin of 19.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 18.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.06% in the last 1 week, and is up 17.56% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 16.07% and the 50-Day Moving Average is 28.01%.The 200 Day SMA reached 66.64% Ariad Pharmaceuticals Inc. is up 61.17% in the last 3-month period. Year-to-Date the stock performance stands at 93.92%.
ARIAD Pharmaceuticals (ARIA) : Currently there are 4 street experts covering ARIAD Pharmaceuticals (ARIA) stock. The most bullish and bearish price target for the stock is $13 and $9 respectively for the short term. The average price target of all the analysts comes to $11. The estimated standard deviation from the target is $1.83.
For the current week, the company shares have a recommendation consensus of Buy. ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $11.61 and touched an intraday high of $12.13 on Friday. During the day, the stock corrected to an intraday low of $11.55, however, the bulls stepped in and pushed the price higher to close in the green at $12.12 with a gain of 3.59% for the day. The total traded volume for the day was 10,641,369. The stock had closed at $12.12 in the previous trading session.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).